VF
DRMA icon

Virtu Financial’s Dermata Therapeutics DRMA Stock Holding History

Virtu Financial’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-90
Closed -$8K – 1556
2023
Q4 		$8K Buy
+90
New +$9.75K ﹤0.01% 1429
2023
Q3 		– Sell
-214
Closed -$53K – 1442
2023
Q2 		$53K Buy
+214
New +$58.4K ﹤0.01% 1135
2022
Q4 		– Sell
-30
Closed -$37K – 1736
2022
Q3 		$37K Buy
+30
New +$46.8K ﹤0.01% 1261
2021
Q4 		– Sell
-9
Closed -$101K – 1818
2021
Q3 		$101K Buy
+9
New +$106K 0.01% 1148

Other funds holding DRMA

TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Virtu Financial's DRMA Position: Q1 2024 in Review

Virtu Financial sold out of Dermata Therapeutics (DRMA) in Q1 2024, closing a stake of 90 shares — an estimated $8K sold.

Virtu Financial first reported a position in DRMA in Q3 2021 and held it in 4 quarters. The position peaked at $101K in Q3 2021. 6 funds tracked by Wall St. Rank hold DRMA as of Q1 2024.

  • Virtu Financial reported no remaining Dermata Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Virtu Financial sold 90 Dermata Therapeutics shares in Q1 2024, an estimated $8K.
  • Virtu Financial first reported a position in Dermata Therapeutics in Q3 2021 and held it in 4 quarters.
  • Virtu Financial's Dermata Therapeutics position peaked at $101K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.